🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Simvastatin

    Aurinia Pharmaceuticals

    Drug-drug Interaction

    phase 1 small molecule completed

    1 trial

  2. Simvastatin

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  3. Single Dose Pharmacokinetics and Relative Bioavailability of Sayana Press via Upper Arm Injection Relative to Anterior Thigh and Abdomen

    Pfizer Australia Pty Ltd

    long-term female contraception

    phase 1 other active

    1 trial

  4. Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in patients with advanced solid tumors.

    Fondazione Telethon ETS

    Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry

    phase 1 other active

    1 trial

  5. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  6. Sotagliflozin (SOTA) followed by 3 drugs in a random order

    LEXICON PHARMACEUTICALS, INC.

    Platelet Function and Reactivity Tests

    phase 1 small molecule active

    1 trial

  7. Stem Cell

    EuroGen Pharmaceuticals Ltd

    Neurological; Disorder, Nervous System

    phase 1 mab terminated

    1 trial

  8. Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

    Arrowhead Pharmaceuticals Ireland Limited

    spinocerebellar ataxia type 2

    phase 1 other active

    1 trial

  9. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  10. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  11. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  12. Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

    Novartis Pharmaceuticals

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  13. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  14. Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  15. Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

    IONIS PHARMACEUTICALS INC

    Multiple System Atrophy

    phase 1 other active

    1 trial

  16. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  17. TAK-137 5 mg tablet, TAK-137 placebo tablet

    Takeda

    Healthy Japanese Adult Male

    phase 1 small molecule terminated

    1 trial

  18. TAK-653 Placebo

    NEUROCRINE BIOSCIENCES INC

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  19. TAK-951 Placebo

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. TGD001 SAD study in healthy volunteers

    Lacuna Pharma Pty Ltd

    A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers

    phase 1 other active

    1 trial

  21. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  22. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Healthy Subjects (HS)

    phase 1 small molecule completed

    1 trial

  23. TNX-102 SL 5.6 mg

    Tonix Pharmaceuticals Holding

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  24. TNX-102 SL Tablet

    Tonix Pharmaceuticals Holding

    Pharmakokinetic

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources